Bone health in prostate cancer patients receiving androgen-deprivation therapy: The role of bisphosphonates

Prostate Cancer and Prostatic Diseases

Volumn 11, Issue 1, 2008, Pages 13-19

  Polascik, T J ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; ANTIANDROGEN; ANTIEMETIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; CREATININE; ETIDRONIC ACID; GONADORELIN AGONIST; IBANDRONIC ACID; OPIATE DERIVATIVE; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ARTHRALGIA; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BONE NECROSIS; BONE PAIN; CANCER PATIENT; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DOSAGE SCHEDULE COMPARISON; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS DISEASE; EVIDENCE BASED MEDICINE; FLU LIKE SYNDROME; FRACTURE; HEALING IMPAIRMENT; HEARTBURN; HUMAN; JAW DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MYALGIA; NAUSEA; OSTEOLYSIS; OSTEOPOROSIS; PAIN ASSESSMENT; PARESTHESIA; PERIODONTAL DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; RETROSTERNAL PAIN; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SOFT TISSUE DISEASE; SOFT TISSUE INFECTION; SPINAL CORD COMPRESSION; TOOTH DISEASE; TOOTH PAIN; TREATMENT DURATION; VOMITING;

ANDROGEN ANTAGONISTS; BONE DISEASES; DIPHOSPHONATES; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 39149100666     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4501019     Document Type: Review

References (33)

1. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000; 164: 1248-1253.
2. Casey R, Love W, Mendoza C, Reymond D, Zarenda M. Zoledronic acid reduces bone loss in men with prostate cancer undergoing androgen deprivation therapy. The 2006 Multi-disciplinary Prostate, Cancer Symposium, 24-26 February 2006; San Francisco, Calif. Abstract 184.
3. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25: 1038-1042.
4. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N, Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-2012.
5. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Shoenfeld DA et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345: 948-955.
6. Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV, the Zometa US05 Investigators. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006; 176: 972-978.
7. Israeli RS, Rosenberg S, Saltzstein D, Gottesman JE, Goldstein HR, Hull GW et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen-deprivation therapy. Clin Genitourin Cancer 2007; 5: 271-277.
8. Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: A practical review and guide for the clinician. Urol Clin North Am 2004; 31: 331-352.
9. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164.
10. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Phashos CL. Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897-7903.
11. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006; 175: 136-139.
12. Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology 2004; 64: 335-340.
13. Agarwal MM, Khandelwal N, Mandal AK, Rana SV, Gupta V, Chandra Mohan V et al. Factors affecting bone mineral density in patients with prostate carcinoma before and after orchiectomy. Cancer 2005; 103: 2042-2052.
14. Kiratli J, Srinivas S, Perkash I, Terris MK. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 2001; 57: 127-132.
15. Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology 2007; 70: 122-126.
16. Morote J, Martinez E, Trilla E, Esquena S, Abascal JM, Encabo G et al Osteoporosis during continuous androgen deprivation: Influence of the modality and length of treatment. Eur Urol 2003; 44: 661-665.
17. Wegner H. Clinical experience with zoledronic acid: A urologist's perspective. Eur Urol Suppl 2006; 5: 551-552.
18. Lipton A. Pathophysiology of bone metastases: How this knowledge may lead to therapeutic intervention. J Support Oncol 2004; 2: 205-213.
19. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: A randomized trial. Ann Intern Med 2007; 146: 416-424.
20. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. A randomized, placebo-controlled trial of zoledronic add in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
21. Saad F, Gleason DM, Murray R, Techkmedyian S, Venner P, Lacombe L et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882.
22. Zometa® (package insert). Novartis Pharmaceuticals Corporation: East Hanover, NJ, 2006.
23. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J et al Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-610.
24. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: Results or a 2-year prospective study. J Clin Endocrinol Metab 2001; 86: 5252-5255.
25. Saad F, Higano CS, Sartor O, Colombel M, Murray R, Mason MD et al. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer 2006; 4: 257-262.
26. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003; 21: 4277-4284.
27. Eastham J, McKiernan J, Gleason D, Zheng M, Saad F. Effect of zoledronic acid on bone pain and skeletal morbidity in patients with advanced prostate cancer; analysis by baseline pain. J Clin Oncol 2005; 23 (16S): 393s. Abstract 4561.
28. Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005; 10: 52-62.
29. Polascik TJ, Given RW, Metzer C, Julan SR, Vestal JC, Karlin GS et al Open-label hial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology 2005; 66: 1054-1059.
30. National Comprehensive, Cancer Network Inc. The NCCN (2.2005) Prostate Cancer Clinical Practice Guidelines in Oncology 2006. Available at: http://www.nccn.org. Accessed on 10 October 2006. To view the most recent and complete version of the guideline, go online to www.nccn.org.
31. Fosamax® (package insert). Merck & Co, Inc: Whitehouse Station, NJ, 2006.
32. Ruggerio S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM et al Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006; 2: 7-14.
33. Hoff AO, Toth BB, Altundag K, Guarneri V, Adamus A, Nooka AK et al Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J Clin Oncol 2006; 24: 475S. Abstract 8528.